1. Medtech Insight

INS 2017: Positive Initial Data Put Axonics On Next Big Wave Of Sacral Neuromodulation Growth

 
• By Tina Tan

Axonics Modulation Technologies may be running against medtech giant Medtronic in the field of sacral neuromodulation for overactive bladder, but the smaller player is unfazed. Encouraging preliminary findings from its clinical study, revealed this week at the INS 2017 neuromodulation conference, is giving Axonics' technology the validation it needs. CEO Raymond Cohen is confident that the special features offered by the r-SNM system will galvanize what is already a fast-growing market.

Positive initial results from a multicenter clinical study of the r-SNM system for treating overactive bladder (OAB) has further consolidated Axonics Modulation Technologies Inc.'s standing as a notable rival – despite its modest stature – to medtech giant Medtronic PLC in the sacral neuromodulation (SNM) market.

The RELAX-OAB study was initiated in June last year, after the r-SNM system was CE marked, and it has enrolled 51 overactive bladder patients with symptoms of urinary urgency incontinence and urgency

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gynecology and Urology

More from Device Area